Vanguard Group Inc Brainstorm Cell Therapeutics Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

A detailed history of Vanguard Group Inc transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,510,640 shares of BCLI stock, worth $1.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,510,640
Previous 1,510,640 -0.0%
Holding current value
$1.84 Million
Previous $513,000 32.36%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$0.34 - $0.74 $37,279 - $81,138
109,647 Added 7.83%
1,510,640 $513,000
Q1 2024

May 10, 2024
SELL
$0.28 - $0.66 $6,248 - $14,729
-22,317 Reduced 1.57%
1,400,993 $784,000
Q2 2023

Aug 14, 2023
SELL
$2.0 - $3.2 $10,446 - $16,713
-5,223 Reduced 0.37%
1,423,310 $2.93 Million
Q4 2022

Feb 10, 2023
BUY
$1.37 - $4.42 $864 - $2,789
631 Added 0.04%
1,428,533 $2.34 Million
Q2 2022

Aug 12, 2022
BUY
$2.71 - $3.6 $18,436 - $24,490
6,803 Added 0.48%
1,427,902 $3.94 Million
Q1 2022

May 13, 2022
SELL
$2.92 - $4.19 $27,661 - $39,691
-9,473 Reduced 0.66%
1,421,099 $4.78 Million
Q4 2021

Feb 14, 2022
SELL
$2.81 - $4.23 $5,190 - $7,812
-1,847 Reduced 0.13%
1,430,572 $5.72 Million
Q3 2021

Nov 12, 2021
BUY
$3.14 - $4.09 $61,522 - $80,135
19,593 Added 1.39%
1,432,419 $4.73 Million
Q2 2021

Aug 13, 2021
BUY
$3.01 - $4.01 $4.25 Million - $5.67 Million
1,412,826 New
1,412,826 $5.37 Million

Others Institutions Holding BCLI

# of Institutions
41
Shares Held
10.8M
Call Options Held
160K
Put Options Held
30.5K
View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

BCLI Quotes by TradingView
  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $44.5M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email